Literature DB >> 20857252

Modeling disease progression in acute stroke using clinical assessment scales.

Kristin E Karlsson1, Justin J Wilkins, Fredrik Jonsson, Per-Henrik Zingmark, Mats O Karlsson, E Niclas Jonsson.   

Abstract

This article demonstrates techniques for describing and predicting disease progression in acute stroke by modeling scores measured using clinical assessment scales, accommodating dropout as an additional source of information. Scores assessed using the National Institutes of Health Stroke Scale and the Barthel Index in acute stroke patients were used to model the time course of disease progression. Simultaneous continuous and probabilistic models for describing the nature and magnitude of score changes were developed, and used to model the trajectory of disease progression using scale scores. The models described the observed data well, and exhibited good simulation properties. Applications include longitudinal analysis of stroke scale data, clinical trial simulation, and prognostic forecasting. Based upon experience in other areas, it is likely that application of this modeling methodology will enable reductions in the number of patients needed to carry out clinical studies of treatments for acute stroke.

Entities:  

Mesh:

Year:  2010        PMID: 20857252      PMCID: PMC2977005          DOI: 10.1208/s12248-010-9230-0

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  34 in total

1.  FUNCTIONAL EVALUATION: THE BARTHEL INDEX.

Authors:  F I MAHONEY; D W BARTHEL
Journal:  Md State Med J       Date:  1965-02

2.  Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.

Authors:  W M Clark; S Wissman; G W Albers; J H Jhamandas; K P Madden; S Hamilton
Journal:  JAMA       Date:  1999-12-01       Impact factor: 56.272

3.  PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

Authors:  Lars Lindbom; Pontus Pihlgren; E Niclas Jonsson; Niclas Jonsson
Journal:  Comput Methods Programs Biomed       Date:  2005-09       Impact factor: 5.428

4.  High-dose tirilazad for acute stroke (RANTTAS II). RANTTAS II Investigators.

Authors:  E C Haley
Journal:  Stroke       Date:  1998-06       Impact factor: 7.914

5.  A longitudinal model for non-monotonic clinical assessment scale data.

Authors:  Fredrik Jonsson; Scott Marshall; Michael Krams; E Niclas Jonsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-12       Impact factor: 2.745

6.  Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators.

Authors:  K R Lees; K Asplund; A Carolei; S M Davis; H C Diener; M Kaste; J M Orgogozo; J Whitehead
Journal:  Lancet       Date:  2000-06-03       Impact factor: 79.321

7.  Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial.

Authors:  G Ladurner; P Kalvach; H Moessler
Journal:  J Neural Transm (Vienna)       Date:  2004-12-07       Impact factor: 3.575

Review 8.  Neuroprotection for acute stroke: making clinical trials work.

Authors:  K W Muir; D G Grosset
Journal:  Stroke       Date:  1999-01       Impact factor: 7.914

9.  Multinational randomised controlled trial of lubeluzole in acute ischaemic stroke. European and Australian Lubeluzole Ischaemic Stroke Study Group.

Authors:  H C Diener
Journal:  Cerebrovasc Dis       Date:  1998 May-Jun       Impact factor: 2.762

10.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.

Authors:  W Hacke; M Kaste; C Fieschi; R von Kummer; A Davalos; D Meier; V Larrue; E Bluhmki; S Davis; G Donnan; D Schneider; E Diez-Tejedor; P Trouillas
Journal:  Lancet       Date:  1998-10-17       Impact factor: 79.321

View more
  2 in total

Review 1.  Disease progression and neuroscience.

Authors:  Nick Holford
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-04-17       Impact factor: 2.745

2.  Comparisons of Analysis Methods for Proof-of-Concept Trials.

Authors:  K E Karlsson; C Vong; M Bergstrand; E N Jonsson; M O Karlsson
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-01-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.